Monitoring of seasonal variability in bronchial hyper-responsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy

Clinical and Experimental Allergy

Volumn 33, Issue 7, 2003, Pages 873-881

  Polosa, Riccardo ^a   Gotti, F Li ^a   Mangano, G ^a   Mastruzzo, C ^a   Pistorio, M P ^a   Crimi, N ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Adenosine challenge; Bronchial hyper responsiveness; Induced sputum; Parietaria allergy; Seasonal allergic rhinitis; Specific immunotherapy

Indexed keywords

ADENOSINE PHOSPHATE; ALUTARD; METHACHOLINE; PARIETARIA POLLEN VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADULT; ALLERGIC RHINITIS; ARTICLE; BRONCHUS HYPERREACTIVITY; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EOSINOPHIL; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MALE; PARIETARIA JUDAICA; POLLEN; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION; SPUTUM ANALYSIS; SYMPTOMATOLOGY;

ADENOSINE MONOPHOSPHATE; ADULT; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTOR AGENTS; CELL COUNT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; PARIETARIA; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SEASONS; SPUTUM;

EID: 0037772149     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2003.01676.x     Document Type: Article

References (41)

1. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351:1225-32.
2. Howard TD, Wiesch DG, Koppelman GH, Postma DS, Meyers DA, Bleecker ER. Genetics of allergy and bronchial hyperresponsiveness. Clin Exp Allergy 1999; 29(Suppl 2):86-9.
3. Togias A. Systemic cross-talk between the lung and the nose. Am J Respir Crit Care Med 2001; 164:726-7.
4. Sparrow D, O'Connor G, Colton T, Barry CL, Weiss ST. The relationship of nonspecific bronchial responsiveness to the occurrence of respiratory symptoms and decreased levels of pulmonary function: the Normative Aging Study. Am Rev Respir Dis 1987; 135:1255-60.
5. Hopp RJ, Townley RG, Biven RE, Bewtra AK, Nair NM. The presence of airway reactivity before the development of asthma. Am Rev Respir Dis 1990; 141:2-8.
6. Braman SS, Barrows AA, DeCotiis BA, Settipane GA, Corrao WM. Airway hyperresponsiveness in allergic rhinitis: a risk factor for asthma. Chest 1987; 91:671-4.
7. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J Allergy Clin Immunol 2002; 109:251-6.
8. Bradley BL, Azzawi M, Jacobson M et al. Eosinophils, T-lymphocytes, mast cells, neutrophils and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparisons with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 88:661-74.
9. Djukanovic R, Lai CKW, Wilson JW et al. Bronchial mucosal manifestation of atopy: a comparison of markers of inflammation between atopic asthmatics, atopic non-asthmatics and healthy controls. Eur Respir J 1992; 5:538-44.
10. Polosa R, Ciamarra I, Mangano G et al. Bronchial hyperresponsiveness and airway inflammation markers in non asthmatics with allergic rhinitis. Eur Respir J 2000; 15:30-5.
11. Gerblich AA, Schwartz HJ, Chester EH. Seasonal variation of airway function in allergic rhinitis. J Allergy Clin Immunol 1986; 77:676-81.
12. Madonini E, Briatico-Vangosa G, Pappacoda A, Maccagni G, Cardani A, Saporiti F. Seasonal increase of bronchial reactivity in allergic rhinitis. J Allergy Clin Immunol 1987; 79:358-63.
13. Boulet LP, Morin D, Milot J, Turcotte H. Bronchial responsiveness increases after seasonal antigen exposure in non-asthmatic subjects with pollen-induced rhinitis. Ann Allergy 1989; 63:114-9.
14. D'Amato G, Spieksma M, Liccardi G et al. Pollen-related allergy in Europe. Allergy 1998; 53:567-78.
15. Di Lorenzo G, Mansueto P, Melluso M et al. Non-specific airway hyperresponsiveness in mono-sensitive Sicilian patients with allergic rhinitis. Its relationship to total serum IgE levels and blood eosinophils during and out of the pollen season. Clin Exp Allergy 1997; 27:1052-9.
16. Barnes PJ. Is immunotherapy for asthma worthwhile? N Engl J Med 1996; 334:531-2.
17. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases A WHO position paper. J Allergy Clin Immunol 1998; 102(4 Part 1):531-42.
18. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hayfever uncontrolled by antiallergic drugs. BMJ 1991; 302:265-9.
19. Durham SR, Walker SM, Varga E-M et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999; 341:468-75.
20. Prosperini G, Rajakulasingam K, Cacciola RR et al. Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. J Allergy Clin Immunol 2002; 110:855-61.
21. Polosa R, Phillips GD, Rajakulasingam K, Holgate ST. The effect of inhaled ipratropium bromide alone and in combination with oral terfenadine on bronchoconstriction provoked by adenosine 5,′-monophosphate and histamine in asthma. J Allergy Clin Immunol 1991; 87:939-47.
22. Viegas M, Gomez E, Brooks J, Davies RJ. Changes in mast cell numbers in and out of the pollen season. Int Arch Allergy Appl Immunol 1987; 82:275-7.
23. Feoktistov I, Polosa R, Holgate ST, Biaggioni I. Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol Sci 1998; 19:148-53.
24. Polosa R, Ng WH, Crimi N et al. Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am J Respir Crit Care Med 1995; 151(3 Part 1):624-9.
25. Polosa R, Rorke S, Holgate ST. Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Thorax 2002; 57:649-54.
26. Holgate ST, Roche W, Church MK. The role of the eosinophils in asthma. Am Rev Respir Dis 1991; 143:566-70.
27. Chakir J, Laviolette M, Turcotte H, Boutet M, Boulet LP. Cytokine expression in the lower airways of nonasthmatic subjects with allergic rhinitis: influence of natural allergen exposure. J Allergy Clin Immunol 2000; 106:904-10.
28. Hassim Z, Maronese SE, Kumar RK. Injury to airway epithelial cells by pollen enzymes. Thorax 1998; 53:368-71.
29. Motojima S, Frigas E, Loegering DA, Gleich GJ. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis 1989; 139:801-5.
30. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139:806-17.
31. Piacentini GL, Vicentini L, Mazzi P, Chilosi M, Martinati L, Boner AL. Mite-antigen avoidance can reduce bronchial epithelial shedding in allergic asthmatic children. Clin Exp Allergy 1998; 28:561-7.
32. Ariano R, Kroon AM, Augeri G, Canonica GW, Passalacqua G. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy 1999; 54:313-9.
33. D'Amato G, Kordash TR, Liccardi G, Lobefalo G, Cazzola M, Freshwater LL. Immunotherapy with Alpare in patients with respiratory allergy to Parietaria pollen: a two year double-blind placebo-controlled study. Clin Exp Allergy 1995; 25:149-58.
34. D'Amato G, Liccardi G, Russo M, Saggese M, D'Amato M. Measurement of serum levels of eosinophil cationic protein to monitor patients with seasonal respiratory allergy induced by Parietaria pollen (treated and untreated with specific immunotherapy). Allergy 1996; 51:245-50.
35. Passalacqua G, Albano M, Riccio A et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104:964-8.
36. Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, Marsico SA. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 162:2048-52.
37. Walker SM, Pajno G, Torres-Lima M Wilson DR, Durham SR. Grass pollen immunotherapy in seasonal rhinitis and asthma: a randomized controlled trial. J Allergy Clin Immunol 2001; 107:87-93.
38. Rak S, Bjornson A, Hakanson L, Sorenson S, Venge P. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991; 88:878-88.
39. Kohno Y, Minoguchi K, Oda N et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol 1998; 102(6 Part 1):927-34.
40. Otsuka H, Mezawa A, Onishi M, Okubo K, Seki H, Okuda M. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991; 21:115-20.
41. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644-51.